VERY-RARE CANCERGI CancerWHO 5th Edition Classification

Appendiceal Carcinoma

Very Rare Malignancy (1–5 cases per 1,000,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

A group of tumours of the appendix ranging from low-grade mucinous neoplasms, which spread by filling the abdomen with mucin (pseudomyxoma peritonei), to high-grade adenocarcinomas that behave like aggressive colorectal cancer. Most are found incidentally after an appendicectomy for suspected appendicitis.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Refer all appendiceal mucinous neoplasms to a peritoneal surface malignancy centre
Who It Affects

Adults, median 50-60; slight female predominance in mucinous types

Annual Incidence

Approximately 1-2 per million per year, though rising with better recognition

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Symptoms of acute appendicitis - right lower abdominal pain
Progressive abdominal distension and increasing waist size
A new hernia, or an ovarian mass in women
Change in bowel habit
Frequently no symptoms at all before surgery

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

KRASGNAS - characteristic of low-grade mucinous tumoursTP53 in high-grade disease

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Appendicectomy for small, low-grade, completely excised tumours

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Right hemicolectomy for high-grade or larger tumours

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Systemic chemotherapy (FOLFOX/FOLFIRI-type) for high-grade or unresectable disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Somatostatin analogues for appendiceal neuroendocrine tumours

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Strongly grade-dependent. Low-grade mucinous disease treated with complete cytoreduction and HIPEC has five-year survival above 80%, and long-term cure is achievable. High-grade adenocarcinoma with signet-ring cells has a considerably worse outlook.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Randomised evidence on HIPEC continues to evolve; molecular characterisation is separating appendiceal from colorectal biology and guiding trial design.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Appendiceal Carcinoma

Browse All Oncologists

Dr. Muhammad M. Sardi

Surgical Oncologist

30+ yrs exp

Mercy Medical Center

Baltimore, USA

Surgical OncologyAppendiceal CancerCRS+HIPEC
Vetted DirectoryConsult Specialist

Dr. Tan Ker Kan

Surgical Oncologist

15+ yrs exp

NUH

Singapore, Singapore

Surgical OncologyAppendiceal TumorsCRS+HIPEC
Vetted DirectoryConsult Specialist

Prof. Norman Carr

Gastrointestinal Oncologist

25+ yrs exp

Basingstoke Hospital

Basingstoke, United Kingdom

GI OncologyPeritoneal MalignancyAppendix Tumors
Vetted DirectoryConsult Specialist

Dr. Anil Heroor

Surgical Oncologist

20+ yrs exp

Private Practice

Mumbai, India

Surgical OncologyHIPECAppendiceal Mucinous Carcinoma
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

very-rare

Angioimmunoblastic T-cell Lymphoma (AITL)

very-rare

Esthesioneuroblastoma

very-rare

Adenoid Cystic Carcinoma (ACC)

very-rare

Fibrolamellar Hepatocellular Carcinoma (FL-HCC)

Independent Tumor Board Review

Facing a Diagnosis of Appendiceal Carcinoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult